Ascelia Pharma AB
STO:ACE

Watchlist Manager
Ascelia Pharma AB Logo
Ascelia Pharma AB
STO:ACE
Watchlist
Price: 4.75 SEK 1.06% Market Closed
Market Cap: 551.1m SEK

Operating Margin
Ascelia Pharma AB

0%
Current
0%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-71.4m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
Ascelia Pharma AB
STO:ACE
551.1m SEK N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
337.9B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
165.8B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
141.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.6B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
130.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Ascelia Pharma AB
Glance View

Market Cap
551.1m SEK
Industry
Biotechnology

Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.

ACE Intrinsic Value
33.4 SEK
Undervaluation 86%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-71.4m
/
Revenue
0
What is the Operating Margin of Ascelia Pharma AB?

Based on Ascelia Pharma AB's most recent financial statements, the company has Operating Margin of 0%.

Back to Top